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Background: Ophthalmopathy is a common manifestation of Graves’ disease (GD) occurring in up to 50% of
patients. Mild eye signs are also common in patients with Hashimoto’s thyroiditis. Whilst a genetic predisposition to
GD has been demonstrated this is not the case for the ophthalmopathy which often runs a separate course.
Objective: We determined the prevalences of eye and eyelid signs and positive thyroid and orbital antibody tests
in first and second degree relatives from a single family with multiple cases of Graves’ disease, ophthalmopathy and
Hashimoto’s thyroiditis.
Design: The study cohort comprised 16 subjects from the same family, 4 probands namely, 3 with GD and one
with Hashimoto’s thyroiditis and hypothyroidism and 12 of their euthyroid first or second degree relatives. We
measured antibodies against calsequestrin (CASQ1) and collagen XIII in an enzyme-linked-immunosorbent assays
and TSH-Receptor (TSH-R) antibodies as i) TSH-R binding inhibiting immunoglobulin (TBII) and ii) thyroid stimulating
immunoglobulin (TSI). Eye signs were classified and quantified using the clinical activity score (CAS), NOSPECS
classes, Nunery types 1 and 2 and the margin-reflex-distance (MRD) as a measure of upper eyelid retraction (UER).
Main outcomes: Whilst significant ophthalmopathy was uncommon in the relatives, mild eye signs, in particular
UER, were demonstrated in about a third of them. The presence of eye signs was moderately, but not significantly,
associated with the detection of CASQ1 and collagen XIII antibodies, but not TSH-R antibodies.
Conclusion: Our study demonstrates a significant prevalence of positive orbital antibody tests and ophthalmopathy
in probands with thyroid autoimmunity and their euthyroid relatives, favouring a role of genetic factors in the
development of ophthalmopathy in patients with thyroid autoimmunity.
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Graves’ disease (GD) is the most common form of hyper-
thyroidism, affecting up to 1% of the population [1]. There
is a marked gender differences in prevalence with a 5–10
fold excess in females and a significant clustering of dis-
ease in families, with 40-50% of patients reporting at
least one family member with a thyroid disorder [2]. GD* Correspondence: jackw@med.usyd.edu.au
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reproduction in any medium, provided the oris considered to be a heterogeneous autoimmune dis-
order affecting, with varying degrees of severity, the thy-
roid, eyes and skin [3]. McKenzie [4] has defined GD as
“a multi system disorder of unknown aetiology, charac-
terized by one or more of three clinical entities; 1) hyper-
thyroidism associated with diffuse hyperplasia of the
thyroid gland 2) infiltrative ophthalmology and 3) infil-
trative dermopathy (localized pretibial myxedema)”.
GD is a classical autoimmune disorder in which target-
ing of thyroid antigens, in particular the thyroid stimu-
lating hormone (TSH) receptor (TSH-R), by antibodies
and sensitized T lymphocytes leads to proliferation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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There is a genetic susceptibility to autoimmunity which
is triggered by unknown environmental factors [5,6]. Re-
cent studies have identified several genetic susceptibility
loci including human leukocyte antigen (HLA, 6p21.3)
and cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33)
[7]. Several environmental factors have also been eluci-
dated including cigarette smoking, psychosocial stress,
iodine intake, intrauterine growth, bacterial and viral
infections and drugs such as interferon [8].
Ophthalmopathy is a common manifestation of auto-
immune thyroid disease occurring in about 50% of
patients with GD where it is called Graves’ ophthalmopa-
thy (GO) [9], and in about 25% of patients with Hashi-
moto’s thyroiditis [10]. Ophthalmopathy may develop as
a result of cross-reaction against a thyroid and orbital
tissue antigen(s) in orbital connective tissue and eye
muscle. Candidate orbital connective tissue antigen in-
clude the TSH-R, which is also expressed in the orbital
fat and pre adipocytes [11-14] and possibly eye muscle as
well [15], and the fibroblast cell membrane antigen colla-
gen type XIII [16,17]. Of the several eye and eyelid
muscle antigens identified [3] the skeletal muscle cal-
cium binding protein calsequestrin (CASQ1) is the best
candidate [17-19]. In order to further study the role of
orbital antibodies in the pathogenesis of ophthalmopa-
thy, and to address a possible genetic role, we have deter-
mined the prevalences of eye and eyelid signs and
positive thyroid and orbital antibody tests in first and
second degree relatives from a single family with mul-
tiple cases of thyroid autoimmunity.
Materials and methods
Clinical Subjects
The study involved 16 subjects, 10 females and 6 males
aged 13–76 (mean age 40 years) from the same family
in Melbourne, Victoria (Figure 1). Within this branch
of the family there are three cases of confirmed GD,
both male, one case of Hashimoto’s thyroiditis and
hypothyroidism and 12 first or second degree relatives of
whom 6, 4 females and 2 males had a history of thyroid
disease of unknown aetiology. Diagnosis of thyroid dis-
ease was based on standard clinical criteria and con-
firmed by thyroid function testing and thyroid antibody
measurements. The grade, severity and activity of any
ophthalmopathy were classified as; 1) Nunery types 1
(without restrictive myopathy) or 2 (with restrictive
myopathy) [20] (2) as the clinical activity score (CAS)
(0–10) of Mourits et al. [21] which is a measure of
disease activity 3) Werner’s NOSPECS class [22] and 4)
the upper eyelid margin-reflex distance (MRD) which is
the distance between the centre of the pupillary light re-
flex and the upper eyelid margin with the eye in primary
gaze, as a measure of upper eyelid retraction (UER). AnMRD of> 5 mm, which correlates with an UER score of
>+ using our assessment protocol, is taken as significant
UER. Local Ethical Committee approval was received for
the study and informed consent of participating subjects
was obtained.
Serum antibody measurement
The presence and level of serum orbital antibodies in
probands and their relatives were determined using an
enzyme-linked immunosorbent assay (ELISA). This pro-
cedure has been described in previous publications by
this laboratory [10,17-19] and is standard. The antigens
used were i) highly purified rabbit skeletal muscle
CASQ1 which shares 97% homology with human calse-
questrin and ii) recombinant human collagen XIII.
Results were expressed as optical density (OD) at 405
nM. A positive test was taken as an OD> the upper limit
of the reference range, which was 194 for CASQ1 and
193 for collagen XIII. Serum TSH-R antibodies were
measured as i) TSH-R binding inhibiting immunoglobu-
lin (TBII) where a positive test was taken as a level
of> 1.5 IU/L and ii) thyroid stimulating immunoglobulin
(TSI) using fresh human thyroid cells as source of cyclic
AMP (cAMP) following stimulation with test serum and
a cAMP ELISA kit where a positive test was, taken as a
%B/BO> 19%, following the manufacturers instructions
and reference ranges.
Statistical analysis
Differences in prevalences of orbital and TSH-R anti-
bodies were determined using the Mann–Whitney test
for a non parametric data. A P value of <0.5 was taken
as significant in all assessments.
Results
The study cohort comprised 16 subjects from a single
family, 4 probands of whom 3 had GD and one had
Hashimoto’s thyroiditis and hypothyroidism and 12 first
or second degree relatives. We measured antibodies
against CASQ1 and collagen XIII in an ELISA, and
TSH-R antibodies in two assays, and eye signs were clas-
sified and quantified as described in methods.
Prevalence of thyroid dysfunction
At the time of study, all patients and relatives were clin-
ically well and euthyroid. Sera were available from 16
subjects namely, the 4 probands [WH-18, WH-25 and
WH-30 who had GD] and WH-15 who had
hypothyroidism due to Hashimoto’s thyroiditis], and 11
first or second degree relatives. Of these, 3 subjects had
abnormal TSH levels namely, two probands; WH-15
with a high TSH, and WH-18 with a low TSH both of
whom were receiving thyroxine replacement, and one of
the untreated relatives, WH-28, who had a low TSH
Figure 1 Family Tree showing probands with Graves’ disease or Hashimoto’s thyroiditis and their euthyroid relatives, 6 of whom had
“thyroid disease of unknown aetiology”.
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chemically and clinically euthyroid at the time of testing.Thyroid antibodies
Serum from two of the three probands with previously
documented GD namely, WH-25 and WH-30, and from
the hypothyroid subject WH-15, was positive for TPO
antibodies. It is interesting to note that WH-15 has a
daughter (not tested) with Hashimoto’s thyroiditis. Al-
though none of the relatives were clinically or biochem-
ically hyperthyroid, two, WH-29 and WH-31, the
daughters and sisters of two of the Graves’ probands (see
Figure 1), were positive for TPO antibodies (Table 1).TSH-R antibodies, as TBII and TSI, were measured in
most of the subjects. Positive TBII tests were demon-
strated in two probands with GD, WH-30, and WH-25
and TSI tests were borderline positive in one apparently
normal first degree relative, WH-26. The prevalences of
positive TSH-R antibodies in probands vs relatives with
and without ophthalmopathy were not significantly dif-
ferent (Mann–Whitney tests, P =NS).Ophthalmopathy
Next, we examined the 16 probands and relatives for eye
and upper eyelid abnormalities. The overall prevalence
of any eye signs was 37.5%. Three (20%) of the subjects
Table 1 Demographic data, biochemical and immunological findings and treatment of probands with thyroid













TBII TSI L-T4 RAI ATD
Probands GD5 with
ophthalmopathy (n = 3)
52-75 2/1 1.84 2 2 0 3 3 1
Other thyroid disorders (n = 1) 77 1/0 6.52 1 0 0 1 0 0
Relatives No documented thyroid disorders (n = 11) 13-54 7/5 1.26 2 0 1 0 0 0
1 TSH = thyroid stimulating hormone (normal range 0.3-4.0 mIU/L).
2 TPO = thyroid peroxidase (cut-off titre 100).
3 A positive test for thyroid stimulating antibodies (TSI) was taken as a % B/BO >19%, a positive test for TSH-R binding inhibitory immunoglobulin (TBII) was taken
as >1.5 IU/Litre.
4 Number of patients treated with thyroxine (L-T4),
131I or antithyroid drugs (ATD).
5 GD = Graves’ disease.
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(WH-18, WH-21) and two second-degree relatives (WH-
49, WH-50) had mild ophthalmopathy (CAS= 1) and
one proband (WH-30) had severe ophthalmopathy
(CAS= 5) of many years duration which required cor-
rective eye muscle surgery. Four of the probands (all 3
probands with GD and WH-15 with Hashimoto’s thyroi-
ditis) also had mild UER and WH-30 had moderate ocu-
lar muscle dysfunction with restricted lateral gaze of the
left eye. The duration of eye signs in these subjects was
difficult to determine as they did not recognize any par-
ticular eye symptoms. All 4 probands with autoimmuneTable 2 Prevalence of eye signs in probands and first or
second degree relatives from a single family with
multiple cases of thyroid autoimmunity
Subject CAS1 UER2 Nunery types 1, 23 NOSPECS classes4
WH-15 1 Yes 1 1
WH-18 2 0 1 2
WH-25 2 0 1 2
WH-26 0 0 0
WH-28 0 0 0
WH-29 0 0 0
WH-30 5 Yes 2 4
WH-31 0 0 0
WH-32 0 0 0
WH-41 0 0 0
WH-42 0 0 0
WH-48 0 0 0
WH-49 1 2 1 1
WH-50 1 0 1 2
WH-51 0 0 0
WH-52 0 0 0
1 CAS =Clinical activity score (CAS) (0–10) as described by Mourits et al
(see ref no. 21).
2 UER =Upper eyelid retraction, taken as a MRD >5 mm which corresponds to
an UER score of>+.
3 see ref no [20].
4 see ref. no [22].thyroid disease, WH-15 with hypothyroidism and WH-
18, WH-25 and WH-30 with GD, had eye signs. The
other relatives were normal (Table 2).
Orbital antibodies
We measured CASQ1 and collagen XIII antibodies in
serum from all 16 subjects; namely, 4 probands and 12
euthyroid first or second degree relatives. Two of the
three probands with GD, WH-18 and WH-30 who was
also positive for TBII (but not for TSI), were positive for
CASQ1 antibodies and one, WH-30, for collagen XIII
antibodies (Table 3). The subject who tested positive for
both antibodies was WH-30, the proband with severe
ophthalmopathy (see Table 2). Of the four euthyroid
relatives with positive eye muscle antibody tests only two
(one with reactivity against CASQ1, WH-41, and one
with reactivity against collagen XIII, WH-29) were first-
degree relatives of probands with autoimmune thyroid
disease. The other two euthyroid subjects with positive
antibody results, WH-49 and WH-50, were the children
of WH-29, i.e. second-degree relatives of probands with
GD (see Figure 1). One of the second-degree relatives
WH-49, had positive CASQ1 and collagen XIII antibody
tests while another, WH-50, had a positive collagen XIII
antibody test only. There was a modest overall correl-
ation between any eye signs and positive antibody re-
activity against CASQ1 and/or collagen XII, I although
this did not reach statistical significance for ether anti-
body (Mann-Witney test P =NS, P =NS respectively)
(Table 3).
Finally, all subjects with Graves’ disease and two first-
degree relatives reported the presence of other auto-
immune disorders (results not shown).
Discussion
Graves’ ophthalmopathy is a common disorder which can
present with either hyperthyroidism or hypothyroidism
or in the apparent absence of thyroid autoimmunity, so
called euthyroid Graves’ disease [9]. The ophthalmopathy
Table 3 Prevalence of CASQ1 and collagen XIII antibodies in probands and first or second degree relatives from a
single family with multiple cases of thyroid autoimmunity
Subjects Subjects Prevalence (%) of positive antibody reactivity
CASQ11 Collagen XIII
Probands GD2 with ophthalmopathy 2 (66%) 1 (33%)
(n= 3)
Other disorders 0 0
(n= 1)
Relatives No documented thyroid disorders 2 (16%) 3 (25%)
(n= 12)
1 CASQ1= skeletal muscle calsequestrin.
2 GD=Graves’ disease.
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Hashimoto’s thyroiditis [10] is presumed to be an auto-
immune disorder of the extraocular muscles and orbital
connective tissue. There is substantial evidence that the
eye muscles are targets of the autoimmune reactions of
“thyroid-associated ophthalmopathy” because more than
90% of Graves’ patients with or without clinical signs of
ophthalmopathy have extraocular muscle enlargement by
orbital imaging techniques [23].
In the present study we determined the prevalence of
CASQ1 and collagen XIII antibodies in serum from pro-
bands and first or second degree relatives of a single
family with multiple cases of thyroid autoimmunity. We
observed a fairly close relationship between CASQ1 and
collagen XIII antibodies and ophthalmopathy, eye signs
including stare and lid lag being demonstrated in all but
one subject with positive eye muscle antibodies, although
this was not significant, possibly because of the small
numbers of subjects studied. Two thirds of those with
positive eye muscle antibodies and eye signs had docu-
mented thyroid disease, 3 with GD and one with
hypothyroidism, whilst two of the six subjects with eye
signs were second-degree relatives of three probands
with GD. It is interesting to note that WH-49 had a TSH
result at the upper limit of normal and detectable anti-
bodies against CASQ1 and collagen XIII, making her an
interesting subject for long term follow-up at risk to de-
velop thyroid dysfunction and/or ophthalmopathy in the
future.
Several groups [24-26] have shown that relatives of
patients with Graves’ disease have an increased preva-
lence of thyroid antibodies compared with controls, as
well as an increased tendency to develop other auto-
immune diseases. The notion that autoimmunity against
the TSH-R is involved in the development of GD and
GO and evidence for increased thyroid antibodies in eu-
thyroid relatives of patients with GD makes a strong case
for the familial inheritance of orbital antibodies as well.
While significant ophthalmopathy is uncommon in rela-
tives of subjects with GD, mild eye signs, in particularupper eyelid abnormalities, associated with eye muscle
antibodies against CASQ1 and collagen XIII, were seen
in about 33% of euthyroid relatives in a single family in
the present study. This raises the possibility of a role for
genetic factors in the development of ophthalmopathy.
In conclusion, it seems likely that the development of
ophthalmopathy in patients with Graves’ hyperthyroid-
ism and Hashimoto’s thyroiditis results from the concur-
rence of several environmental and genetic factors.
Because individual families are small, the best approach
to understanding the “genetic factor” would be to study
large numbers of patients with thyroid autoimmunity
with and without ophthalmopathy, for example looking
for linkages between eye signs and selected polymorph-
isms (SNPs) of the CASQ1 and collagen XIII genes.
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